Last Update 29 Jul 26
Fair value Increased 6.34%HAE: Recent Index Additions And Buybacks Will Face Catalyst Fatigue Risk
Haemonetics' analyst fair value estimate has moved from $62.00 to about $65.93 as analysts factor in recent price target increases tied to perceived Plasma and Hospital upside, sector model updates, and changing expectations around near-term catalysts.
Analyst Commentary
Recent research on Haemonetics shows a mix of optimism around Plasma and Hospital opportunities and caution around how much good news is already reflected in the stock. Several major firms have updated targets and ratings in 2026, which helps you see where expectations and perceived risks currently sit.
On the constructive side, some large firms have raised price targets into the US$90 range and cited potential upside in key business segments. One firm also highlighted the addition of Martin Madaus to the board of directors as an interesting development, given his background in healthcare investments and portfolio company oversight. These points support the view that Haemonetics still has room to execute on its growth plans if management delivers.
At the same time, not all commentary is upbeat. One research house described a "mixed setup" for the broader medical device and diagnostic sector as part of a Q2 earnings preview, even as it raised its Haemonetics target into the US$90 area. This kind of language signals that some analysts see risks around sector sentiment, peer comparisons, or how investors may react to upcoming results.
Citi has made several neutral updates on Haemonetics over the past year, with targets in the US$70s and comments that fundamentals across medical technology are solid. More recently, Citi also highlighted a "downside 90-day catalyst watch" and flagged that the shares were trading at year to date highs. The firm noted that even if Haemonetics beats and raises guidance, the shift in expectations could limit how much extra credit the stock receives.
There have also been price target cuts from other research providers earlier in the period, including JPMorgan and additional firms that reduced targets by mid single digit to low double digit dollar amounts. While the specific reasoning is not detailed here, these changes add to the sense that not every analyst is fully comfortable with the current setup on valuation or execution.
Bearish Takeaways
- Bearish analysts highlight that Haemonetics is trading near year to date highs and flag a "downside 90-day catalyst watch," which signals concern that recent strength in the stock may leave limited room if upcoming results or guidance do not impress.
- Comments that a beat and raise "may not be enough given the shift in expectations" point to the risk that current valuation already bakes in optimistic assumptions, which can make the stock more sensitive to any perceived shortfall.
- Target reductions from firms including JPMorgan and others suggest some analysts see increased execution or growth risk, even if the broader sector backdrop is described as solid.
- References to a "mixed setup" for the medical device and diagnostic sector indicate that macro or sector level concerns could weigh on sentiment toward Haemonetics, even if company specific fundamentals hold steady.
What’s in the News for Haemonetics
- Haemonetics Corporation (NYSE: HAE) was added to the Russell 2500 Value Benchmark, according to index constituent updates.
- The company was also added to the Russell 3000E Value Benchmark, expanding its presence across Russell value indexes.
- Haemonetics joined the Russell 2000 Value Defensive Index and the Russell 2000 Value Benchmark, reflecting inclusion in small cap value and defensive oriented index baskets.
- The company was added to the Russell Small Cap Comp Value Benchmark and the Russell 3000 Value Benchmark, further broadening index coverage for Haemonetics stock.
- From December 28, 2025 to March 28, 2026, Haemonetics repurchased 1,579,255 shares, representing 3.37% of shares, for US$100 million, and completed a total of 3,009,834 shares repurchased, representing 6.34%, for US$175 million under the buyback announced on May 8, 2025, according to company buyback disclosures.
Valuation Changes for Haemonetics
- Fair Value has risen slightly from $62.00 to about $65.93, reflecting updated analyst assumptions in the model.
- Discount Rate has fallen slightly from 8.18% to about 7.99%, which increases the weight placed on Haemonetics' projected cash flows.
- Revenue Growth has edged higher from about 4.97% to about 5.15%, indicating a modestly stronger outlook for revenue expansion in dollar terms.
- Net Profit Margin has moved lower from about 16.36% to about 14.82%, which points to more conservative expectations for earnings in dollar terms relative to sales.
- Future P/E has risen from about 11.8x to about 13.7x, signaling a higher valuation multiple being applied to Haemonetics' expected earnings.
Key Takeaways
- Advances in bloodless surgery and intensifying competition could limit revenue growth and margin improvement in key segments if operational risks are not addressed.
- Exposure to reimbursement pressures, regulatory changes, and supply chain challenges may constrain earnings growth and cash flow sustainability despite strong innovation and partnerships.
- Heavy reliance on core U.S. markets and short-term gains exposes Haemonetics to competitive, regulatory, and cyclical risks that threaten long-term growth and profitability.
Catalysts
About Haemonetics- A medical technology company, provides a suite of hospital technologies solutions in the United States and internationally.
- While Haemonetics benefits from a global demographic tailwind fueled by an aging population and rising chronic diseases-which should ensure longer-term demand for plasma and transfusion products-there is a risk that continued medical advances in bloodless surgery and improved surgical techniques could eventually plateau demand, limiting topline revenue growth over time.
- Although strong innovation in plasma collection platforms and software adoption (especially NexSys and NexLynk) are driving share gains, operational execution risk remains in Vascular Closure and Interventional Technologies, where recent underperformance, increasing competition, and complex customer dynamics could stall expected margin expansion and subdue net margin improvement if not promptly addressed.
- While the company's increasing strategic partnerships and long-term contracts in plasma software promise recurring revenue and improved earnings visibility, reimbursement pressures from government and private payors globally could weigh on gross margins and threaten sustainable EPS growth.
- Even with firm momentum in hemostasis management and TEG 6S adoption, the hospital portfolio is concentrated in the U.S., heightening exposure to potential U.S. healthcare cost containment and regulatory policy changes, which could limit the pace of market expansion and dampen revenue growth if adverse conditions arise.
- Despite long-term growth opportunities in emerging markets driven by improved healthcare access, supply chain fragility, raw material shortages, and higher regulatory hurdles could result in intermittent disruptions and elevated operating expenses, which may constrain operating income growth and pressure long-term cash flow conversion.
Haemonetics Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Haemonetics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Haemonetics's revenue will grow by 5.2% annually over the next 3 years.
- The bearish analysts assume that profit margins will increase from 7.3% today to 14.8% in 3 years time.
- The bearish analysts expect earnings to reach $229.9 million (and earnings per share of $4.95) by about July 2029, up from $97.3 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $257.1 million.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 13.8x on those 2029 earnings, down from 39.9x today. This future PE is lower than the current PE for the US Medical Equipment industry at 29.1x.
- The bearish analysts expect the number of shares outstanding to decline by 5.67% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.99%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Haemonetics' concentration of revenue and growth in three core products, with roughly 80% of revenue generated in the U.S., exposes the company to geographic and product-specific risks; shifts in U.S. healthcare policy or market saturation could limit revenue growth and compress margins over the longer term.
- The company acknowledges increased competition in its Vascular Closure and Interventional Technologies segments, including from low-cost competitors, with recent below-market growth in electrophysiology procedures; if Haemonetics fails to regain competitiveness, this could erode market share, reduce pricing power, and pressure segment revenues and margins.
- Plasma business momentum has been driven in part by one-time software licensing revenue and share gains, while underlying plasma collection volumes in the U.S. were described as flat and macrocyclical; overreliance on near-term pricing and share wins, rather than secular collection growth, could result in slower sustainable revenue expansion if volumes do not recover as projected.
- Investments in expanding salesforce capabilities, restructuring commercial teams, and ongoing R&D are required to address execution gaps and reignite underperforming business lines, but these add to operating expenses and could negatively impact net earnings growth if improvements do not materialize as expected.
- Long-term risks are highlighted by the cyclical nature of plasma collection, heightened productivity among customers reducing total collection needs, and persistent pressure from healthcare consolidation and cost containment, any of which could limit Haemonetics' pricing power, slow top-line growth, and compress operating margins in future years.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Haemonetics is $65.93, which represents up to two standard deviations below the consensus price target of $87.9. This valuation is based on what can be assumed as the expectations of Haemonetics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $104.0, and the most bearish reporting a price target of just $62.0.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.6 billion, earnings will come to $229.9 million, and it would be trading on a PE ratio of 13.8x, assuming you use a discount rate of 8.0%.
- Given the current share price of $85.42, the analyst price target of $65.93 is 29.6% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Haemonetics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
